Intra-Cellular Therapies Inc (ITCI)
69.20
-0.52
(-0.75%)
USD |
NASDAQ |
Mar 28, 16:00
69.16
-0.04
(-0.06%)
After-Hours: 20:00
Intra-Cellular Therapies Research and Development Expense (Quarterly): 50.77M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 50.77M |
September 30, 2023 | 41.55M |
June 30, 2023 | 49.79M |
March 31, 2023 | 38.02M |
December 31, 2022 | 33.86M |
September 30, 2022 | 33.27M |
June 30, 2022 | 38.54M |
March 31, 2022 | 29.04M |
December 31, 2021 | 29.46M |
September 30, 2021 | 27.03M |
June 30, 2021 | 17.30M |
March 31, 2021 | 15.06M |
December 31, 2020 | 14.30M |
September 30, 2020 | 10.28M |
June 30, 2020 | 25.20M |
March 31, 2020 | 16.00M |
December 31, 2019 | 19.07M |
September 30, 2019 | 21.34M |
June 30, 2019 | 23.73M |
March 31, 2019 | 24.99M |
December 31, 2018 | 33.61M |
Date | Value |
---|---|
September 30, 2018 | 35.42M |
June 30, 2018 | 32.44M |
March 31, 2018 | 30.70M |
December 31, 2017 | 26.93M |
September 30, 2017 | 18.47M |
June 30, 2017 | 12.48M |
March 31, 2017 | 21.54M |
December 31, 2016 | 21.18M |
September 30, 2016 | 23.92M |
June 30, 2016 | 25.30M |
March 31, 2016 | 23.43M |
December 31, 2015 | 22.87M |
September 30, 2015 | 28.46M |
June 30, 2015 | 17.76M |
March 31, 2015 | 18.63M |
December 31, 2014 | 11.64M |
September 30, 2014 | 4.046M |
June 30, 2014 | 2.710M |
March 31, 2014 | 2.829M |
December 31, 2013 | 6.130M |
September 30, 2013 | 4.158M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
10.28M
Minimum
Sep 2020
50.77M
Maximum
Dec 2023
27.93M
Average
26.12M
Median
Research and Development Expense (Quarterly) Benchmarks
Insmed Inc | 137.03M |
Ionis Pharmaceuticals Inc | 256.56M |
Fate Therapeutics Inc | 31.82M |
ADMA Biologics Inc | 0.4455M |
Ocugen Inc | 6.342M |